Surgery Partners reported AN Adjusted EBITDA decline of 4.2% in Q4 following projections for continued expanding margins -- Levi & Korsinsky, LLP investigates potential securities law violations
NEW YORK, March 11, 2026 /PRNewswire/ -- Surgery Partners (NASDAQ: SGRY) investors lost money after the Company's Q4 2025 earnings revealed a significant gap between the adjusted figures management highlighted and the Company's GAAP financial results. Shareholders who suffered a loss are encouraged to submit their information here. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
Last quarter, Surgery Partners emphasized its Adjusted EBITDA of $136.4 million for Q3 2025, representing what CEO Eric Evans called "6.1% growth over the prior year and a margin of 16.6%." The adjusted figures were used to support forward guidance and management's repeated claims of "margin expansion" -- yet SGRY shares dropped sharply when the Company announced that Q4 exhibited an Adjusted EBITDA decline of 4.2%, resulting in a shortfall against management's prior guidance.
Shareholders who purchased SGRY and suffered a loss may click here to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
View original content to download multimedia:https://www.prnewswire.com/news-releases/sgry-adjusted-ebitda-fell-shy-of-managements-guided-projections----levi--korsinsky-llp-investigates-302710510.html
SOURCE Levi & Korsinsky, LLP
